Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
MetroHealth CRS
893
mi
from
Cleveland, OH
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
MetroHealth CRS
893
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Penn Therapeutics Crs
1223
mi
from
Philadelphia, PA
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
1425
mi
from
Providence, RI
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
1425
mi
from
Providence, RI
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth Univ. Medical Ctr. CRS
1113
mi
from
Richmond, VA
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth Univ. Medical Ctr. CRS
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
2331
mi
from
San Juan,
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
2331
mi
from
San Juan,
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
31788 Alabama CRS
683
mi
from
Birmingham, AL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
31788 Alabama CRS
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
1168
mi
from
Los Angeles, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
701 University of California, San Diego AntiViral Research Center CRS
1142
mi
from
San Diego, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
701 University of California, San Diego AntiViral Research Center CRS
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
801 University of California, San Francisco HIV/AIDS CRS
1339
mi
from
San Francisco, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
801 University of California, San Francisco HIV/AIDS CRS
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
400
mi
from
Aurora, CO
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
400
mi
from
Aurora, CO
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
610
mi
from
Chicago, IL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center (2702)
610
mi
from
Chicago, IL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center (2702)
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Adult AIDS CRS (201)
1148
mi
from
Baltimore, MD
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Adult AIDS CRS (201)
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
1276
mi
from
Newark, NJ
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
1276
mi
from
Newark, NJ
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
7804 Weill Cornell Chelsea CRS
1225
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
7804 Weill Cornell Chelsea CRS
1225
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Columbia Physicians and Surgeons CRS (30329)
1225
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Columbia Physicians and Surgeons CRS (30329)
1225
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
7803 Weill Cornell Upton CRS
1225
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
7803 Weill Cornell Upton CRS
1225
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Unc Aids Crs
1043
mi
from
Chapel Hill, NC
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Unc Aids Crs
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Greensboro CRS (3203)
1003
mi
from
Greensboro, NC
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS (3203)
1003
mi
from
Greensboro, NC
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
726
mi
from
Cincinnati, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Case CRS (2501)
895
mi
from
Cleveland, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
6201 Penn Therapeutics CRS
1223
mi
from
Philadelphia, PA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
6201 Penn Therapeutics CRS
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Pittsburgh CRS (1001)
971
mi
from
Pittsburgh, PA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Pittsburgh CRS (1001)
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics CRS (3652)
619
mi
from
Nashville, TN
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics CRS (3652)
619
mi
from
Nashville, TN
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Trinity Health and Wellness Center CRS (31443)
348
mi
from
Dallas, TX
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Trinity Health and Wellness Center CRS (31443)
348
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS (31473)
569
mi
from
Houston, TX
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS (31473)
569
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS (1401)
1410
mi
from
Seattle, WA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS (1401)
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Puerto Rico-AIDS CRS (5401)
2331
mi
from
San Juan,
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
2331
mi
from
San Juan,
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
418
mi
from
Saint Louis, MO
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS (2301)
810
mi
from
Columbus, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
810
mi
from
Columbus, OH
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
850
mi
from
Phoenix, AZ
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
850
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1144
mi
from
Orlando, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1144
mi
from
Orlando, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
805
mi
from
Decatur, GA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
805
mi
from
Decatur, GA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
415
mi
from
Saint Louis, MO
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1243
mi
from
Fort Pierce, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1243
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
838
mi
from
Berkley, MI
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
838
mi
from
Berkley, MI
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1282
mi
from
West Palm Beach, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1282
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
643
mi
from
Indianapolis, IN
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1364
mi
from
Springfield, MA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1364
mi
from
Springfield, MA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1209
mi
from
Allentown, PA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1209
mi
from
Allentown, PA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1424
mi
from
Providence, RI
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1424
mi
from
Providence, RI
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
5602
mi
from
Ciudad Autonoma de Buenos Aires,
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
199
mi
from
Kansas City, MO
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
199
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
572
mi
from
Bellaire, TX
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
572
mi
from
Bellaire, TX
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1127
mi
from
Washington,
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1127
mi
from
Washington,
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
340
mi
from
Dallas, TX
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
340
mi
from
Dallas, TX
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1340
mi
from
San Francisco, CA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1252
mi
from
Hillsborough, NJ
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1252
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
676
mi
from
Birmingham, AL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
676
mi
from
Birmingham, AL
Click here to add this to my saved trials